BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten

Roughly a year after closing its mega-acquisition of Celgene Corporation, Bristol Myers Squibb Company dipped into the M&A waters again on 5 October with a $13.1bn buyout of clinical-stage MyoKardia, Inc. based on the commercial prospects of its first-in-class allosteric myosin inhibitor in obstructive hypertrophic cardiomyopathy (HCM).

During a same-day investor call, BMS chief commercial officer Christopher Boerner talked up mavacamten’s potential to change the standard of care for obstructive HCM – currently surgery such as myectomy and symptom-addressing therapies such as beta and calcium-channel blockers – with a potentially disease-modifying therapy that addresses the underlying cause of the disease. MyoKardia unveiled data from the Phase III EXPLORER-HCM study in May in which mavacamten hit both the primary and all secondary endpoints with a solid safety and tolerability profile